Francisco José Márquez-Malaver
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Francisco José Márquez-Malaver has a total of 205 co-authors. Here are the top co-authors by number of shared publications:
- José Antonio Pérez-Simón
Department of Hematology, Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla, (IBIS, CSIC) Universidad de Sevilla, Sevilla, Spain
8 shared publications - David Valcárcel
Myeloid Malignancies Research Group, Vall d’hebron Institute of oncology (VHIO), Hospital Vall d’hebron, Universitat Aùtonoma de Barcelona, Barcelona, Spain
7 shared publications - Lucía López-Corral
Hospital Universitario de Salamanca, Instituto de Investigacion Biomedica de Salamanca (IBSAL), Centro de Investigación del Cancer (IBMCC-USAL, CSIC), Salamanca, Spain
7 shared publications - Jose Francisco Falantes
Department of Hematology University Hospital Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS/CSIC) Sevilla Spain
6 shared publications R. Parody
Hospital Virgen del Rocío Sevilla Spain
5 shared publicationsRocío Parody
Institut Català d'Oncologia, Hospital Duran i Reynals, Barcelona, Spain
5 shared publications
Latest Publications
- Open Access
- 7 November 2019
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 55 (3) , 641-648
Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study
Graft-versus-host disease is the main cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation. First-line treatment is based on the use of high doses of corticosteroids. Unfortunately, second-line treatment for both acute and chronic graft-versus-host disease, remains a challenge. Ruxolitinib has been shown as an effective and safe treatment option for these patients. Seventy-nine patients received ruxolitinib and were evaluated in this retrospective and multicenter study. Twenty-three patients received ruxolitinib for refractory acute graft-versus-host disease after a median of 3 (range 1–5) previous lines of therapy. Overall response rate was 69.5% (16/23) which was obtained after a median of 2 weeks of treatment, and 21.7% (5/23) reached complete remission. Fifty-six patients were evaluated for refractory chronic graft-versus-host disease. The median number of previous lines of therapy was 3 (range 1–10). Overall response rate was 57.1% (32/56) with 3.5% (2/56) obtaining complete remission after a median of 4 weeks. Tapering of corticosteroids was possible in both acute (17/23, 73%) and chronic graft-versus-host disease (32/56, 57.1%) groups. Overall survival was 47% (CI: 23–67%) at 6 months for patients with aGVHD (62 vs 28% in responders vs non-responders) and 81% (CI: 63–89%) at 1 year for patients with cGVHD (83 vs 76% in responders vs non-responders). Ruxolitinib in the real life setting is an effective and safe treatment option for GVHD, with an ORR of 69.5% and 57.1% for refractory acute and chronic graft-versus-host disease, respectively, in heavily pretreated patients.
- 7 November 2019
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 55 (3) , 641-648
Open AccessRuxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study
Graft-versus-host disease is the main cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation. First-line treatment is based on the use of high doses of corticosteroids. Unfortunately, second-line treatment for both acute and chronic graft-versus-host disease, remains a challenge. Ruxolitinib has been shown as an effective and safe treatment option for these patients. Seventy-nine patients received ruxolitinib and were evaluated in this retrospective and multicenter study. Twenty-three patients received ruxolitinib for refractory acute graft-versus-host disease after a median of 3 (range 1–5) previous lines of therapy. Overall response rate was 69.5% (16/23) which was obtained after a median of 2 weeks of treatment, and 21.7% (5/23) reached complete remission. Fifty-six patients were evaluated for refractory chronic graft-versus-host disease. The median number of previous lines of therapy was 3 (range 1–10). Overall response rate was 57.1% (32/56) with 3.5% (2/56) obtaining complete remission after a median of 4 weeks. Tapering of corticosteroids was possible in both acute (17/23, 73%) and chronic graft-versus-host disease (32/56, 57.1%) groups. Overall survival was 47% (CI: 23–67%) at 6 months for patients with aGVHD (62 vs 28% in responders vs non-responders) and 81% (CI: 63–89%) at 1 year for patients with cGVHD (83 vs 76% in responders vs non-responders). Ruxolitinib in the real life setting is an effective and safe treatment option for GVHD, with an ORR of 69.5% and 57.1% for refractory acute and chronic graft-versus-host disease, respectively, in heavily pretreated patients.
- 24 September 2019
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 55 (2) , 419-430
Efficacy of bortezomib to intensify the conditioning regimen and the graft-versus-host disease prophylaxis for high-risk myeloma patients undergoing transplantation
This multicenter phase I trial was designed to evaluate the safety and efficacy of bortezomib (Bz) as part of both the conditioning regimen and the graft-versus-host disease (GvHD) prophylaxis. Patients received fludarabine, melphalan and Bz (days −9 and −2). GVHD prophylaxis consisted of Bz (days +1, +4, and +7), sirolimus (Siro) from day −5 and tacrolimus (Tk) from −3 (except the first five patients that did not receive Tk). Twenty-five patients with poor prognostic multiple myeloma were included. Eleven out of the 19 patients had high-risk features. Out of the 21 patients evaluable at day +100, 14 were in CR (67%) and 7 (33%) in PR. Cumulative incidence (CI) of nonrelapse mortality at 1 year was 24%. CI of grades 2–4 and 3–4 acute GvHD was 35% and 10%, respectively; CI of chronic GvHD was 35% and 55% at 1 and 2 years, respectively. Overall and event free survival at 2 years were 64% and 31%, respectively. Bz as part of the conditioning regimen and in the combination with Siro/tacrolimus for GvHD prophylaxis is safe and effective allowing an optimal disease control early after transplant and reducing the risk of GvHD.
- 24 September 2019
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 55 (2) , 419-430
Efficacy of bortezomib to intensify the conditioning regimen and the graft-versus-host disease prophylaxis for high-risk myeloma patients undergoing transplantation
This multicenter phase I trial was designed to evaluate the safety and efficacy of bortezomib (Bz) as part of both the conditioning regimen and the graft-versus-host disease (GvHD) prophylaxis. Patients received fludarabine, melphalan and Bz (days −9 and −2). GVHD prophylaxis consisted of Bz (days +1, +4, and +7), sirolimus (Siro) from day −5 and tacrolimus (Tk) from −3 (except the first five patients that did not receive Tk). Twenty-five patients with poor prognostic multiple myeloma were included. Eleven out of the 19 patients had high-risk features. Out of the 21 patients evaluable at day +100, 14 were in CR (67%) and 7 (33%) in PR. Cumulative incidence (CI) of nonrelapse mortality at 1 year was 24%. CI of grades 2–4 and 3–4 acute GvHD was 35% and 10%, respectively; CI of chronic GvHD was 35% and 55% at 1 and 2 years, respectively. Overall and event free survival at 2 years were 64% and 31%, respectively. Bz as part of the conditioning regimen and in the combination with Siro/tacrolimus for GvHD prophylaxis is safe and effective allowing an optimal disease control early after transplant and reducing the risk of GvHD.
- 1 August 2019
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 25 (15) , 4616-4623
Vitamin D Modifies the Incidence of Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation Depending on the Vitamin D Receptor (VDR) Polymorphisms
Purpose: The biologically active metabolite of vitamin D3, 1,25-dihydroxyvitamin D3 (vit D) has immunoregulatory properties via binding vitamin D receptor (VDR). In a prospective trial, we previously reported a reduction in the incidence of chronic GvHD (cGvHD) among patients who received vit D after allogeneic stem cell transplantation (allo-HSCT) (Clinical-Trials.gov: NCT02600988). Here we analyze the role of patients and donors VDR Single Nucleotide Polymorphisms (SNPs) on the immunomodulatory effect of vit D. Design: Patients undergoing allo-HSCT were included in a prospective phase I/II clinical trial (Alovita) in three consecutive cohorts: control (without vit D), low-dose (1000 UI/day) and high-dose (5000 UI/day) groups. Vit D was given from day -5 until +100 after transplant. Genotyping of four SNPs of the VDR gene, FokI, BsmI, ApaI and TaqI, were performed using "TaqMan SNP Genotyping Assays". Results: We observed a decrease in the incidence of overall cGvHD at 1 year after allo-HSCT depending on the use or not of vit D among patients with FokI CT genotype (22.5% vs 80%, p=0.0004) and among those patients without BsmI/ApaI/TaqI ATC haplotype (22.2% vs 68.8%, p=0.0005); In a multivariate analysis FokI CT genotype significantly influenced on the risk of cGvHD in patients treated with vit D as compared to the control group (HR 0.143, interaction pFokI CT genotype display the highest benefit from receiving vit D after allo-HSCT.
- 1 August 2019
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 25 (15) , 4616-4623
Vitamin D Modifies the Incidence of Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation Depending on the Vitamin D Receptor (VDR) Polymorphisms
Purpose: The biologically active metabolite of vitamin D3, 1,25-dihydroxyvitamin D3 (vit D) has immunoregulatory properties via binding vitamin D receptor (VDR). In a prospective trial, we previously reported a reduction in the incidence of chronic GvHD (cGvHD) among patients who received vit D after allogeneic stem cell transplantation (allo-HSCT) (Clinical-Trials.gov: NCT02600988). Here we analyze the role of patients and donors VDR Single Nucleotide Polymorphisms (SNPs) on the immunomodulatory effect of vit D. Design: Patients undergoing allo-HSCT were included in a prospective phase I/II clinical trial (Alovita) in three consecutive cohorts: control (without vit D), low-dose (1000 UI/day) and high-dose (5000 UI/day) groups. Vit D was given from day -5 until +100 after transplant. Genotyping of four SNPs of the VDR gene, FokI, BsmI, ApaI and TaqI, were performed using "TaqMan SNP Genotyping Assays". Results: We observed a decrease in the incidence of overall cGvHD at 1 year after allo-HSCT depending on the use or not of vit D among patients with FokI CT genotype (22.5% vs 80%, p=0.0004) and among those patients without BsmI/ApaI/TaqI ATC haplotype (22.2% vs 68.8%, p=0.0005); In a multivariate analysis FokI CT genotype significantly influenced on the risk of cGvHD in patients treated with vit D as compared to the control group (HR 0.143, interaction pFokI CT genotype display the highest benefit from receiving vit D after allo-HSCT.
- 1 April 2017
- Published by Elsevier in Leukemia Research
- Vol. 55, S140
Assessing Prognosis in Patients with Lower-Risk Myelodysplastic Syndromes. Parameters Related to the Probability of Leukemic Progression
- 1 April 2017
- Published by Elsevier in Leukemia Research
- Vol. 55, S140
Assessing Prognosis in Patients with Lower-Risk Myelodysplastic Syndromes. Parameters Related to the Probability of Leukemic Progression
- Open Access
- 30 November 2016
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 22 (23) , 5673-5681
Immunomodulatory Effect of Vitamin D after Allogeneic Stem Cell Transplantation: Results of a Prospective Multicenter Clinical Trial
Purpose: We describe the results of a prospective multicenter phase I/II trial evaluating the impact of the use of vitamin D (VitD) from day −5 to +100 on the outcome of patients undergoing allogeneic transplantation (EudraCT: 2010-023279-25; ClinicalTrials.gov: NCT02600988).Experimental Design: A total of 150 patients were included in three consecutive cohorts of 50 patients each group: control group (CG, not receive VitD); low-dose group (LdD, received 1,000 IU VitD daily); and high-dose group (HdD, 5,000 IU VitD daily). We measured levels of VitD, cytokines, and immune subpopulations after transplantation.Results: No significant differences were observed in terms of cumulative incidence of overall and grades 2–4 acute GVHD in terms of relapse, nonrelapse mortality, and overall survival. However, a significantly lower cumulative incidence of both overall and moderate plus severe chronic GVHD (cGVHD) at 1 year was observed in LdD (37.5% and 19.5%, respectively) and HdD (42.4% and 27%, respectively) as compared with CG (67.5% and 44.7%, respectively; P < 0.05). In multivariable analysis, treatment with VitD significantly decreased the risk of both overall (for LdD: HR = 0.31, P = 0.002; for HdD: HR = 0.36, P = 0.006) and moderate plus severe cGVHD (for LdD: HR = 0.22, P = 0.001; for HdD: HR = 0.33, P = 0.01). VitD modified the immune response, decreasing the number of B cells and naïve CD8 T cells, with a lower expression of CD40L.Conclusions: This is the first prospective trial that analyzes the effect of VitD postransplant. We observed a significantly lower incidence of cGVHD among patients receiving VitD. Interestingly, VitD modified the immune response after allo-SCT. Clin Cancer Res; 22(23); 5673–81. ©2016 AACR.
- 30 November 2016
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 22 (23) , 5673-5681
Open AccessImmunomodulatory Effect of Vitamin D after Allogeneic Stem Cell Transplantation: Results of a Prospective Multicenter Clinical Trial
Purpose: We describe the results of a prospective multicenter phase I/II trial evaluating the impact of the use of vitamin D (VitD) from day −5 to +100 on the outcome of patients undergoing allogeneic transplantation (EudraCT: 2010-023279-25; ClinicalTrials.gov: NCT02600988).Experimental Design: A total of 150 patients were included in three consecutive cohorts of 50 patients each group: control group (CG, not receive VitD); low-dose group (LdD, received 1,000 IU VitD daily); and high-dose group (HdD, 5,000 IU VitD daily). We measured levels of VitD, cytokines, and immune subpopulations after transplantation.Results: No significant differences were observed in terms of cumulative incidence of overall and grades 2–4 acute GVHD in terms of relapse, nonrelapse mortality, and overall survival. However, a significantly lower cumulative incidence of both overall and moderate plus severe chronic GVHD (cGVHD) at 1 year was observed in LdD (37.5% and 19.5%, respectively) and HdD (42.4% and 27%, respectively) as compared with CG (67.5% and 44.7%, respectively; P < 0.05). In multivariable analysis, treatment with VitD significantly decreased the risk of both overall (for LdD: HR = 0.31, P = 0.002; for HdD: HR = 0.36, P = 0.006) and moderate plus severe cGVHD (for LdD: HR = 0.22, P = 0.001; for HdD: HR = 0.33, P = 0.01). VitD modified the immune response, decreasing the number of B cells and naïve CD8 T cells, with a lower expression of CD40L.Conclusions: This is the first prospective trial that analyzes the effect of VitD postransplant. We observed a significantly lower incidence of cGVHD among patients receiving VitD. Interestingly, VitD modified the immune response after allo-SCT. Clin Cancer Res; 22(23); 5673–81. ©2016 AACR.
- 4 July 2016
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 51 (11) , 1537-1539
Differences in stem cell transplantation activity among regions in Spain: an economic explanation
- 4 July 2016
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 51 (11) , 1537-1539
Differences in stem cell transplantation activity among regions in Spain: an economic explanation
- 8 February 2016
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 51 (6) , 863-865
Pre-transplant diastolic but not systolic dysfunction has a negative prognostic impact after allogeneic stem cell transplantation
- 8 February 2016
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 51 (6) , 863-865
Pre-transplant diastolic but not systolic dysfunction has a negative prognostic impact after allogeneic stem cell transplantation
- 3 February 2015
- Published by Wiley in Transplant Infectious Disease
- Vol. 17 (2) , 221-233
Severe infections after single umbilical cord blood transplantation in adults with or without the co‐infusion ofCD34+cells from a third‐party donor: results of a multicenter study from the Grupo Español de Trasplante Hematopoyético (GETH)
Background Umbilical cord blood transplantation (CBT) is an established alternative source of stem cells in the setting of unrelated transplantation. When compared with other sources, single‐unit CBT (sCBT) is associated with a delayed hematologic recovery, which may lead to a higher infection‐related mortality (IRM). Co‐infusion with the sCBT of CD34+ peripheral blood stem cells from a third‐party donor (TPD) (sCBT + TPDCD34+) has been shown to markedly accelerate leukocyte recovery, potentially reducing the IRM. However, to our knowledge, no comparative studies have focused on severe infections and IRM with these 2 sCBT strategies. Methods A total of 148 consecutive sCBT (2000–2010, median follow‐up 4.5 years) were included in a multicenter retrospective study to analyze the incidence and risk factors of IRM and severe viral and invasive fungal infections (IFIs). Neutrophil engraftment occurred in 90% of sCBT (n = 77) and 94% sCBT + TPDCD34+ (n = 71) recipients at a median of 23 and 12 days post transplantation, respectively (P < 0.01). Results The 4‐year IRM was 24% and 20%, respectively (P = 0.7), with no differences at day +30 (5% and 4%, respectively) and day +100 (10% and 8%, respectively). In multivariate analysis early status of the underlying malignancy, cytomegalovirus (CMV)‐seronegative recipient and high CD34+ cell content in the cord blood unit before cryostorage (≥1.4 × 105/kg) were protective of IRM. Among the causes of IRM, bacterial infections and IFIs were more common in sCBT (15% vs. 4%), while CMV disease and parasitic infections were more common in the sCBT + TPDCD34+ cohort (5% vs. 16%). Conclusion These data show that sCBT supported with TPDCD34+ cells results in much shorter periods of post‐transplant leukopenia, but the short‐ and long‐term rates of IRM were comparable to those of sCBT, presumably because immune recovery is equally delayed in both graft types.
- 3 February 2015
- Published by Wiley in Transplant Infectious Disease
- Vol. 17 (2) , 221-233
Severe infections after single umbilical cord blood transplantation in adults with or without the co‐infusion ofCD34+cells from a third‐party donor: results of a multicenter study from the Grupo Español de Trasplante Hematopoyético (GETH)
Background Umbilical cord blood transplantation (CBT) is an established alternative source of stem cells in the setting of unrelated transplantation. When compared with other sources, single‐unit CBT (sCBT) is associated with a delayed hematologic recovery, which may lead to a higher infection‐related mortality (IRM). Co‐infusion with the sCBT of CD34+ peripheral blood stem cells from a third‐party donor (TPD) (sCBT + TPDCD34+) has been shown to markedly accelerate leukocyte recovery, potentially reducing the IRM. However, to our knowledge, no comparative studies have focused on severe infections and IRM with these 2 sCBT strategies. Methods A total of 148 consecutive sCBT (2000–2010, median follow‐up 4.5 years) were included in a multicenter retrospective study to analyze the incidence and risk factors of IRM and severe viral and invasive fungal infections (IFIs). Neutrophil engraftment occurred in 90% of sCBT (n = 77) and 94% sCBT + TPDCD34+ (n = 71) recipients at a median of 23 and 12 days post transplantation, respectively (P < 0.01). Results The 4‐year IRM was 24% and 20%, respectively (P = 0.7), with no differences at day +30 (5% and 4%, respectively) and day +100 (10% and 8%, respectively). In multivariate analysis early status of the underlying malignancy, cytomegalovirus (CMV)‐seronegative recipient and high CD34+ cell content in the cord blood unit before cryostorage (≥1.4 × 105/kg) were protective of IRM. Among the causes of IRM, bacterial infections and IFIs were more common in sCBT (15% vs. 4%), while CMV disease and parasitic infections were more common in the sCBT + TPDCD34+ cohort (5% vs. 16%). Conclusion These data show that sCBT supported with TPDCD34+ cells results in much shorter periods of post‐transplant leukopenia, but the short‐ and long‐term rates of IRM were comparable to those of sCBT, presumably because immune recovery is equally delayed in both graft types.
- Open Access
- 1 January 2015
- Published by Elsevier in Leukemia Research
- Vol. 39 (1) , 52-57
Multivariable time-dependent analysis of the impact of azacitidine in patients with lower-risk myelodysplastic syndrome and unfavorable specific lower-risk score
- 1 January 2015
- Published by Elsevier in Leukemia Research
- Vol. 39 (1) , 52-57
Open AccessMultivariable time-dependent analysis of the impact of azacitidine in patients with lower-risk myelodysplastic syndrome and unfavorable specific lower-risk score